Gerontology

Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis

Retrieved on: 
Thursday, February 23, 2023
Biomarker, Principal investigator, Safety, University, CIRM, Mayo Clinic, Gerontology, Physiology, Research, OA, Patient, Arthralgia, UC Davis School of Veterinary Medicine, Inflammation, Ageing, California Institute for Regenerative Medicine, NIH, Osteoarthritis, Disability, AAV, HIV disease progression rates, PALO, Clinical professor, Women's health, University of Leeds, DSM-IV codes, Regenerative medicine, Pharmaceutical industry, Health, Rheumatology, Orthopedic surgery

The funding will be used to support Genascence's Phase 1b clinical trial of GNSC-001 in knee osteoarthritis (OA), as well as phase-appropriate manufacturing activities.

Key Points: 
  • The funding will be used to support Genascence's Phase 1b clinical trial of GNSC-001 in knee osteoarthritis (OA), as well as phase-appropriate manufacturing activities.
  • "We applaud the Genascence team for tackling one of the most prevalent degenerative diseases.
  • The Phase 1b clinical trial entitled, "A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study Evaluating GNSC-001 Safety, Pharmacodynamics, and Biomarkers in Knee Osteoarthritis," is designed to enroll 50 patients with OA.
  • "We are honored to have CIRM award this funding to help advance GNSC-001, our lead clinical program in OA where we hope to demonstrate transformative results for patients."

CHC: Creating Healthier Communities Announces New President and CEO Jean C. Accius, PhD

Retrieved on: 
Wednesday, February 1, 2023
Florida State University, Centers for Medicare & Medicaid Services, CHC, Accius, Ageing, Retirement, AARP, Head, Medicare, National Association, Cleveland Cavaliers, University, Gerontology, Health, Research, Senior, Harvard University School of Mining and Practical Geology, Business administration, Bachelor of Business Administration, Stanford Graduate School of Business, Health equity, Executive education, Public health, National Association of Corporate Directors, American University, Doctor of Philosophy, Management, Philosophy, Science

ALEXANDRIA , Va., Feb.1, 2023 /PRNewswire-PRWeb/ -- CHC: Creating Healthier Communities, a national nonprofit that removes the barriers to good health and equity, today announced Jean C. Accius, PhD as its new president and CEO.

Key Points: 
  • ALEXANDRIA , Va., Feb.1, 2023 /PRNewswire-PRWeb/ -- CHC: Creating Healthier Communities, a national nonprofit that removes the barriers to good health and equity, today announced Jean C. Accius, PhD as its new president and CEO.
  • "I was drawn to CHC's powerful mission and dedicated board and staff team," said Dr. Jean C. Accius.
  • "Leading CHC has been the highlight of my 40-year nonprofit career," said Thomas G. Bognanno, president and CEO at CHC.
  • To ensure a smooth transition and demonstrate his full support for the new CEO, current CEO Thomas G. Bognanno will remain with CHC through March 31.

NIA-Funded a2 Collective Awards First Tranche of $40M to Spur Innovation at the Intersection of AI, Technology, and Aging in the United States

Retrieved on: 
Monday, January 9, 2023
Palliative care, Orangi Pilot Project, Harvard Medical School, Delirium, Economics, Virtual reality, MD, Research, Gerontology, AITC, National Institute on Aging, Artificial intelligence, Collaboratory, Nursing, NIA, Aircraft, Social isolation, Private sector, Alzheimer's disease, Dementia, MBA, CERT Coordination Center, Frailty, Comorbidity, University of Massachusetts Amherst, Hospital, Visual impairment, Growth, Medicine, RN, JH, AI, Health, Machine learning, University, Natural language processing, Johns Hopkins University, Engineering, Robotics, Brigham and Women's Hospital, Doctor of Philosophy, Woman, Caregiver, Pharmaceutical industry, Medical device, Fine chemical, Ageing

WASHINGTON, Jan. 9, 2023 /PRNewswire/ -- The a2 Collective announced today the selection of 33 pilot projects for a2 Pilot Awards funding as part of a national AgeTech competition that has allocated $40 million to fund technology demonstration projects over the next five years. The a2 Pilot Awards support projects seeking to improve care and health outcomes for older Americans, including individuals with Alzheimer's disease and related dementias (AD/ADRD), and their caregivers.

Key Points: 
  • The a2 Pilot Awards support projects seeking to improve care and health outcomes for older Americans, including individuals with Alzheimer's disease and related dementias (AD/ADRD), and their caregivers.
  • The selection of finalists for the second annual a2 Pilot Awards is currently underway, with announcement of awardees anticipated in spring 2023.
  • Visit a2collective.ai/awardees to view the full list and descriptions of all 33 projects selected for funding in the first a2 Pilot Awards cohort.
  • The a2 Collective is funded by grants U24AG073094, P30AG073104, P30AG073105, and P30AG073107 from the National Institute on Aging, part of the National Institutes of Health.

Kim M. Kubasek Named CEO of Smithtown, NY-Based Developmental Disabilities Institute

Retrieved on: 
Thursday, August 4, 2022
Father, Chairperson, Bachelor of Arts, Richard Barker (life sciences and healthcare leader), Knowledge, St. Charles Medical Center – Bend, Workforce, Bridgeport & Port Jefferson Ferry, DDI, American College, Health administration, Administration, Retirement, Parent, Baruch College, Icahn School of Medicine at Mount Sinai, Business administration, Autism, Continuing care retirement communities in the United States, Saint, Mother, Disability in Canada, Jefferson, Staten Island University Hospital, Seton Hall University, Master of Business Administration, Residential care, Medicine, Psychology, Gerontology, Medicine

SMITHTOWN, N.Y., Aug.4, 2022 /PRNewswire-PRWeb/ -- Developmental Disabilities Institute (DDI) names Kim M. Kubasek Chief Executive Officer of the Smithtown, NY-based nonprofit that provides special education and therapeutic intervention services for adults and children with autism and other developmental disabilities. Ms. Kubasek previously served as DDI's Chief Operating Officer since joining the organization in 2010. She replaces longtime DDI CEO, John Lessard, who announced his retirement earlier this year.

Key Points: 
  • Developmental Disabilities Institute (DDI) names Kim M. Kubasek Chief Executive Officer of the Smithtown, NY-based nonprofit that provides special education and therapeutic intervention services for adults and children with autism and other developmental disabilities.
  • SMITHTOWN, N.Y., Aug.4, 2022 /PRNewswire-PRWeb/ -- Developmental Disabilities Institute (DDI) names Kim M. Kubasek Chief Executive Officer of the Smithtown, NY-based nonprofit that provides special education and therapeutic intervention services for adults and children with autism and other developmental disabilities.
  • Ms. Kubasek previously served as DDI's Chief Operating Officer since joining the organization in 2010.
  • For more than 60 years, Developmental Disabilities Institute (DDI) has provided compassionate personal care to meet the emotional, educational, therapeutic, and vocational needs of children and adults with autism and other developmental disabilities.

Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease

Retrieved on: 
Monday, April 4, 2022
Dementia, Risk, LinkedIn, Milken Institute, Greater, Indiana University, Neurology, Government budget balance, Diagnosis, AD, Neurodegeneration, Caregiver, Informatics, Research, Krembil Research Institute, Alzheimer's Disease International, Geisinger Commonwealth School of Medicine, AI, Cancer, Intelligence, Integrity, Quality of life, Health, Artificial intelligence, Association, Purdue University, Technology, Ageing, Twitter, PDM, Data, Gerontology, Physician, Instagram, Eisai, Patient, Medical device, Residential care, Medical imaging, Pharmaceutical industry, Geisinger, Alzheimer's disease, Facebook

DANVILLE, Pa. and NUTLEY, N.J., April 4, 2022 /PRNewswire/ -- Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer's disease (AD). If effective, the AI tool could potentially be developed to support the early detection and staging of cognitive impairment and dementia, leading to appropriate additional testing for the clinical, biological diagnosis and treatment of dementias such as AD.

Key Points: 
  • The research collaboration will study the use of an algorithm trained on a set of de-identified patient data to identify individuals likely to have cognitive impairment.
  • The algorithm, known as a Passive Digital Marker (PDM), was developed and tested by researchers at Purdue University and Indiana University.
  • The Geisinger-Eisai team will evaluate the PDM in Geisinger's de-identified dataset to determine its potential to detect cognitive impairment, which may suggest early signs of dementia.
  • "Early and accurate diagnosis and treatment of these conditions can drastically improve outcomes and quality of life for both patients and caregivers."

New White Paper Available at the IARFC® Store - Financial Gerontology

Retrieved on: 
Friday, March 25, 2022
Gerontology, Financial gerontology, Death, Physical disability, Special adviser (UK), MRFC, Knowledge, Ageing, International Association, Dementia, Registered, White paper, Disease, Insurance

MIDDLETOWN, Ohio, March 25, 2022 /PRNewswire-PRWeb/ -- According to the author, Dr. James Flanagan, MRFC®… It important to note that aging is heterogeneous and not normative. In other words, there is no one way to age and the path of every individual is different. Additionally, aging is not synonymous with disease. Not everyone will experience significant cognitive decline or physical disability as they grow older. There are people that live until old age and death without experiencing either of these phenomena. We do know for certain that as people age, they will encounter significant life transitions that will require reaction and adaptation and many of those key pivotal events will require that need to consulting professionals of insight and direction. Financial preparedness shapes many of these events. The expertise of a Financial Gerontologist, a trained professional who understands financial planning from a life course perspective cannot be understated.

Key Points: 
  • The International Association of Registered Financial Consultants (IARFC) releases its most current White Paper examining the area of Financial Gerontology.
  • This informative paper lays out the importance of a trained professional who understands financial planning on a holistic level when constructing a financial plan for older clients.
  • This paper probes the following factors to consider under the following topics:
    What Makes a Financial Gerontologist Different from a Financial Consultant?
  • This publication is free and can be accessed by going to the IARFC Store and downloading this White Paper along with prior papers.

Mablink Bioscience Announces Appointment of Its Head of Preclinical Research and Development

Retrieved on: 
Tuesday, March 15, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Doctor of Philosophy, CSO, Technology, Czech Academy of Sciences, Patient, CDO, Molecular biology, Therapeutic index, List of life sciences, Research, Acceleration, ADC, CEO, Cancer, A-DNA, Charles University, Science, Engineering, Phase 1, Fine chemical, Biochemistry, Gerontology, Control, Pharmacology, PSARlink™, Mablink Bioscience, PSARLINK™, MABLINK BIOSCIENCE

(Mablink), a biotechnology company developing a pipeline of antibody-drug conjugates (ADCs) based on its proprietary PSARlink drug-linker technology to treat cancers with high unmet needs, today announced the appointment of its Head of Preclinical Research and Development: Lenka Kyrych Sadilkova, PhD.

Key Points: 
  • (Mablink), a biotechnology company developing a pipeline of antibody-drug conjugates (ADCs) based on its proprietary PSARlink drug-linker technology to treat cancers with high unmet needs, today announced the appointment of its Head of Preclinical Research and Development: Lenka Kyrych Sadilkova, PhD.
  • Jean-Guillaume Lafay, CEO of Mablink, declared that: We are delighted and honored that Dr. Kyrych Sadilkova, a seasoned ADC expert, is joining Mablink.
  • Warren Viricel, CSO of Mablink, said: Dr. Kyrych Sadilkova is a very strong addition to our scientific team.
  • Mablink is developing its own pipeline of ADCs targeting several cancers with high unmet medical needs.

Alliance for Aging Research Statement on HHS Announcement Regarding CMS Reconsideration of Medicare Part B Premium Increase

Retrieved on: 
Monday, January 10, 2022
CMS, Research, Ageing, MHS, Mab, Collection, Disease, Part, Medicare Part D, Alzheimer's Drug Discovery Foundation, Department, United States Department of Health and Human Services, Biogen, CED, Medicare, Alliance for Aging Research, Gerontology, Color, HHS, Amyloid, FDA, Health insurance, Pharmaceutical industry, Alzheimer's disease

CMS previously announced the standard monthly premium for Medicare Part B enrollees would increase to $170.10 for 2022, an increase of $21.60 from $148.50 in 2021, and cited the new Alzheimer's drug as the reason behind half the increase.

Key Points: 
  • CMS previously announced the standard monthly premium for Medicare Part B enrollees would increase to $170.10 for 2022, an increase of $21.60 from $148.50 in 2021, and cited the new Alzheimer's drug as the reason behind half the increase.
  • Unfortunately, CMS was not transparent about how it calculated the large Part B premium increase attributed to the new Alzheimer's therapy.
  • Moreover, we hope that Secretary Becerra encourages Medicare to provide "coverage to label" for all FDA-approved mAB therapies that target amyloid for Alzheimer's disease.
  • Aduhelm was approved under the FDA's accelerated approval program, which requires a phase 4 confirmatory trial to verify clinical benefit.

Mental Health Symptoms on the Rise Among the Visually Impaired

Retrieved on: 
Friday, July 30, 2021
Ophthalmology, Branches of biology, Vision, Gerontology, Visual impairment, Macular degeneration, Geriatrics, Ageing, Macula of retina, Medical signs, AMD Alliance International

New studies now indicate that mental health symptoms among those with vision loss are being diagnosed five times higher than the national average.

Key Points: 
  • New studies now indicate that mental health symptoms among those with vision loss are being diagnosed five times higher than the national average.
  • As baby boomers age and face age-related diseases such as macular degeneration, the incidence of vision loss or blindness is expected to double by 2050.
  • Geriatricians and behavioral health experts agree that among this aging population vision loss has risen to the forefront as a public health concern.
  • Hadley recently launched its new online learning platform, Hadley.edu , built on many months of research and development and based on the needs, wants and desires of visually impaired adults.

C-MOR Consortium Releases Findings on Excess Mortality from the Pandemic in 22 Countries

Retrieved on: 
Friday, July 30, 2021
Articles, Academic disciplines, Demography, Epidemiology, Death, Gerontology, Mortality displacement, Doomsday scenarios, Pandemic

They launched the COVID-19 Mortality (C-MOR) Consortium which welcomed countries from around the world and focused on measuring excess mortality.

Key Points: 
  • They launched the COVID-19 Mortality (C-MOR) Consortium which welcomed countries from around the world and focused on measuring excess mortality.
  • As such, the Consortium could more accurately measure how the pandemic affected mortality in countries across the globe.
  • For five of these countries (Cape Verde, Cyprus, Georgia, Slovenia, and Ukraine) this is the first published analysis on excess mortality.
  • The authors note that the countries with increased excess mortality tended to have limited or delayed control measures, and vice-versa.